Alhan, Canan <br/><br/>
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.  [electronic resource] 

 -  Cytometry. Part B, Clinical cytometry  May 2014 
 - 207-15 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1552-4957 
<br/><br/><label>Standard No.: </label>10.1002/cyto.b.21160  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Azacitidine--therapeutic use<br/>Biomarkers, Pharmacological--analysis<br/>Bone Marrow Cells--classification<br/>Female<br/>Flow Cytometry<br/>Humans<br/>Immunophenotyping<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Leukemia, Myelomonocytic, Chronic--drug therapy<br/>Male<br/>Middle Aged<br/>Myelodysplastic Syndromes--drug therapy<br/>Myeloid Progenitor Cells--classification<br/>Prognosis<br/>Research Design<br/>Retrospective Studies<br/>Risk Factors